FDA considers two new executive posts and approves first-of-its-kind early drug and ketone‑glucose wearable

The Health and Human Services department is reportedly evaluating the creation of two additional senior positions within the FDA, a step that could increase agency oversight.

In recent approvals, the FDA cleared a drug ahead of its scheduled review deadline, marking an unusually fast decision.

The agency also authorized a wearable device capable of simultaneously monitoring ketone and glucose levels, a first for such combined metabolic tracking.

These actions illustrate the FDA’s ongoing efforts to adapt its regulatory framework and expand its portfolio of innovative medical products.